File Download
Supplementary

Conference Paper: An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma

TitleAn investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma
Authors
Issue Date2012
PublisherAmerican Association for Cancer Research.
Citation
The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. How to Cite?
AbstractBACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ...
DescriptionPoster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429
Persistent Identifierhttp://hdl.handle.net/10722/149198

 

DC FieldValueLanguage
dc.contributor.authorWong, LLYen_US
dc.contributor.authorLam, IPYen_US
dc.contributor.authorWong, TYNen_US
dc.contributor.authorLai, WLen_US
dc.contributor.authorZhou, Yen_US
dc.contributor.authorHung, WYen_US
dc.contributor.authorChing, YPen_US
dc.date.accessioned2012-06-22T06:29:49Z-
dc.date.available2012-06-22T06:29:49Z-
dc.date.issued2012en_US
dc.identifier.citationThe 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012.en_US
dc.identifier.urihttp://hdl.handle.net/10722/149198-
dc.descriptionPoster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429-
dc.description.abstractBACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ...-
dc.languageengen_US
dc.publisherAmerican Association for Cancer Research.-
dc.relation.ispartofAnnual Meeting of the American Association for Cancer Researchen_US
dc.titleAn investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, LLY: lapywong@hku.hken_US
dc.identifier.emailLai, WL: bennywll@hku.hken_US
dc.identifier.emailZhou, Y: yzhou@hku.hken_US
dc.identifier.emailChing, YP: ypching@hku.hken_US
dc.identifier.authorityChing, YP=rp00469en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros199949en_US
dc.publisher.placeUnited States-
dc.description.otherThe 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012.-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats